We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-0.51%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$123M
AUM Growth
+$14.6M
Cap. Flow
+$35.4M
Cap. Flow %
28.69%
Top 10 Hldgs %
95.81%
Holding
15
New
3
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
LXEO icon
Lexeo Therapeutics
LXEO
+$26.8M
2
ENGN icon
enGene Therapeutics
ENGN
+$10M
3
ENGNW icon
enGene Therapeutics Warrants
ENGNW
+$365K

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXEO icon
1
Lexeo Therapeutics
LXEO
$366M
$29M 23.46%
+2,157,623
New +$26.8M
REPL icon
2
Replimune Group
REPL
$814M
$25.3M 20.5%
3,001,319
– –
NUVB icon
3
Nuvation Bio
NUVB
$2.24B
$22.8M 18.44%
15,072,340
– –
ENGN icon
4
enGene Therapeutics
ENGN
$122M
$10.4M 8.46%
+1,131,175
New +$10M
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.95M 7.25%
309,846
– –
SPRB
6
Spruce Biosciences
SPRB
$119M
$6.33M 5.13%
28,814
– –
KRON
7
DELISTED
Kronos Bio
KRON
$4.77M 3.87%
3,818,283
– –
IMA
8
ImageneBio Inc
IMA
$63.1M
$4.43M 3.59%
187,427
– –
SANA icon
9
Sana Biotechnology
SANA
$885M
$3.44M 2.79%
843,750
– –
THRX
10
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.88M 2.33%
711,479
– –
IMUX icon
11
Immunic
IMUX
$182M
$2.68M 2.17%
178,816
– –
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.96M 1.59%
251,270
– –
ENGNW icon
13
enGene Therapeutics Warrants
ENGNW
$3.75M
$404K 0.33%
+475,077
New +$365K
SNTI icon
14
Senti Biosciences Holdings
SNTI
$12.6M
$129K 0.1%
19,579
– –
ALPN
15
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-153,700
Closed -$1.76M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q4 2023 Portfolio in Review

As of Q4 2023, Omega Fund Management held 15 positions worth $123M, up 13% from $109M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Omega Fund Management deployed $35.4M of net new capital in Q4 2023, opening 3 new positions. Its largest new stake was Lexeo Therapeutics: 2,157,623 shares worth $29M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the most notable exit was Alpine Immune Sciences Inc, an estimated $1.76M sold.

  • Omega Fund Management's largest Q4 2023 buy was Lexeo Therapeutics: 2,157,623 shares worth $29M.
  • Omega Fund Management fully exited Alpine Immune Sciences Inc in Q4 2023, selling an estimated $1.76M.
  • Omega Fund Management's ten largest holdings make up 96% of its $123M portfolio in Q4 2023.
  • Omega Fund Management opened 3 new positions and closed 1 in Q4 2023.
  • Omega Fund Management's portfolio value rose 13% quarter-over-quarter to $123M.

Based on Omega Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.